Treatment of genotype 2 and 3 chronic hepatitis C virus-infected patients

World Journal of Gastroenterology

Volumn 11, Issue 39, 2005, Pages 6188-6192

  Wietzke Braun, Perdita ^a   Meier, Volker ^a   Neubauer Saile, Katrin ^a   Mihm, Sabine ^a   Ramadori, Giuliano ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Alpha interferon; Chronic hepatitis C virus infection; Daily dose interferon therapy; Genotype 2 and 3

Indexed keywords

RECOMBINANT ALPHA2A INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG RESPONSE; FEMALE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; GENOTYPE; HEMOLYSIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; KIDNEY DYSFUNCTION; LEUKOPENIA; MALE; MONOTHERAPY; MYALGIA; PATIENT CARE; PATIENT COMPLIANCE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RIGOR; TERATOGENESIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VIROLOGY;

EID: 30644461311     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i39.6188     Document Type: Article

References (26)

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from bloodborne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-362
2. Hoofnagle JH. Course and Outcome of hepatitis C. Hepatology 2002; 36: S21-S29
3. Cohen J. The Scientific Challenge of Hepatitis C. Science 1999; 285: 26-30
4. Wietzke-Braun P, Braun F, Sattler B, Ramadori G, Ringe B. Initial steroid-free immunosuppression after liver transplantation in recipients with hepatitis C virus related cirrhosis. World J Gastroenterol 2004; 10: 2213-2217
5. Di Bisceglie AM. Hepatitis C and Hepatocellular Carcinoma. Hepatology 1997; 26: 34S-38S
6. Hoofnagle JH, Mullen KD, Jones DB, Rustgi VK, Di Bisceglie A, Hellahan C, Park Y, Meschievitz C, Jones EA. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon: a preliminary report. N Engl J Med 1986; 315: 1575-1578
7. McHutchison JG, Gordon S, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman Z, Ling MH, Cort S, Albrecht JK. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485-1492
8. Lai MY, Kao JH, Yang PM, Wang JT, Chen PJ, Chan KW, Chu JS, Chen DS. Long term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 1996; 111: 1307-1312
9. Chemello L, Cavalletto L, Bernardinello E, Guido M, Pontisso P, Alberti A. The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C. J Hepatology 1995; 23: 8-12
10. Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O. Randomized, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. Lancet 1998; 351: 83-87
11. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, Zarski PJ. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24: 778-789
12. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J. Randomized trial of interferon alpha2b plus ribavirin for 48 wk or for 24 wk versus interferon alpha2b plus placebo for 48 wk for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426-1432
13. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Konry K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of cluonic hepatitis C: a randomised trial. Lancet 2001; 338: 958-965
14. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982
15. Keating GM, Curran MP. Peginterferon-α-2a (40 kD) plus ribavirin. A review of its use in the management of chronic hepatitis C. Drugs 2003; 63: 1-29
16. Wills RJ. Clinical pharmacokinetics of interferons. Clin Pharmacokinet 1990; 19: 390-399
17. Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997; 26: 226-231
18. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. Hepatitis C viral dynaniies in vivo and the antiviral efficacy of interferon alfa therapy. Science 1998; 282: 103-107
19. Zeuzem S, Schmidt JM, Lee JH, von Wagner M, Teuber G, Roth WK. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover. Hepatology 1998; 29: 245-252
20. Mihm S, Hartmann H, Fayyazi A, Ramadori G. Preferential virological response to interferon-alpha 2a in patients with chronic hepatitis C infected by virus genotype 3a and exhibiting a low gamma-GT/ALT ratio. Dig Dis Sci 1996; 41: 1256-1264
21. Wietzke-Braun P, Meier V, Braun F, Ramadori G. Combination of low-dose' ribavirin and interferon alfa-2a therapy followed by interferon alfa-2a monotherapy in chronic HCV-infected non-responders and relapsers after interferon alfa-2a monotherapy. World J Gastroenterol 2001; 7: 222-227
22. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O'Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brunda MJ. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000- 343: 1666-1672
23. Schalm SW, Hansen BE, Chemello L, Bellobuono A, Brouwer JT, Weiland O, Cavalletto L, Schvarcz R, Ideo G, Alberti A. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. J Hepatol 1997; 26: 961-966
24. Bekkering FC, Brouwer JT, Leroux-Roels G, van Vlierberghe H, Elewaut A, Schalm SW. Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy. J Hepatol 1998; 28: 960-964
25. Cornberg M, Hüppe D, Wiegand J, Felten G, Wedemeyer H, Marms MP. Treatment of chronic Hepatitis C with Peg-Interferon alpha-2b and ribavirin: 24 wk of therapy are sufficient for HCV genotype 2 and 3. Z Gastroenterol 2003; 41: 517-522
26. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM. Peginterferon alpha-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355